ATAI Life Sciences BV (ATAI) - Total Liabilities
Based on the latest financial reports, ATAI Life Sciences BV (ATAI) has total liabilities worth $66.10 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ATAI long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
ATAI Life Sciences BV - Total Liabilities Trend (2019–2025)
This chart illustrates how ATAI Life Sciences BV's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ATAI total assets.
ATAI Life Sciences BV Competitors by Total Liabilities
The table below lists competitors of ATAI Life Sciences BV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gold Road Resources Ltd
AU:GOR
|
Australia | AU$382.05 Million |
|
Bank Mega Tbk
JK:MEGA
|
Indonesia | Rp122.53 Trillion |
|
FRASERS PROPERTY
F:1IQ
|
Germany | €22.95 Billion |
|
Autobio Diagnostics Co Ltd
SHG:603658
|
China | CN¥2.99 Billion |
|
HC Semitek Corp
SHE:300323
|
China | CN¥7.53 Billion |
|
Guangzhou Zhujiang Brewery Co Ltd
SHE:002461
|
China | CN¥5.35 Billion |
|
Aerospace CH UAV Co Ltd
SHE:002389
|
China | CN¥2.14 Billion |
|
Turkiye Sigorta AS
IS:TURSG
|
Turkey | TL132.02 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down ATAI Life Sciences BV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ATAI Life Sciences BV balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ATAI Life Sciences BV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ATAI Life Sciences BV (2019–2025)
The table below shows the annual total liabilities of ATAI Life Sciences BV from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $88.54 Million | +106.71% |
| 2024-12-31 | $42.83 Million | -12.87% |
| 2023-12-31 | $49.16 Million | +23.91% |
| 2022-12-31 | $39.67 Million | +40.66% |
| 2021-12-31 | $28.21 Million | +74.33% |
| 2020-12-31 | $16.18 Million | +592.64% |
| 2019-12-31 | $2.34 Million | -- |
About ATAI Life Sciences BV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more